|
| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 63
| Issue : 1 | Page : 24-28 |
Pharmacoeconomic evaluation of diabetic nephropathic patients attending nephrology department in a tertiary care hospital
JV Jose1, M Jose2, P Devi1, R Satish3
1 Department of Pharmacology, St. John's National Academy of Health Sciences, Bengaluru, Karnataka, India
2 Department of Pharmacology, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, India
3 Department of Nephrology, St. John's National Academy of Health Sciences, Bengaluru, Karnataka, India
Correspondence Address:
P Devi
Department of Pharmacology, St. John's National Academy of Health Sciences, Bengaluru, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.194199
Aims: To evaluate the cost of pharmacotherapy and its determinants in diabetic nephropathy (DN) in the nephrology department of a tertiary care hospital. Materials and Methods: A prospective observational study was conducted among adult patients visiting nephrology outpatient department (February-July 2015). Data on demography, investigations, and medications prescribed, direct cost and indirect costs were analyzed. We used Chi-squared test for categorical variables and multivariate linear regression analysis to identify determinants of cost of pharmacotherapy and total cost. Results: Of 100 patients, 50 were above 60 years and 75 were male. Ninety-seven patients had hypertension, which was the most common comorbidity. The majority (60 patients) belonged to Stage 5 DN and 59 patients were on dialysis. The mean number of drugs per patient was 7.60 ± 2.44. The total monthly cost per patient amounted to INR 24,203.27 with total direct cost of INR 21,013.90 (87%) and indirect cost of INR 3189.30 (13%). The monthly cost of dialysis and pharmacotherapy per patient were INR 9060.00 (37%) and INR 2535.98 (11%), respectively. Stage of DN (unstandardized coefficient, B = 7553.96, 95% confidence interval [CI] [6175.09-8932.82], P < 0.001) was a significant determinant of total cost. Number of drugs (B = 636.694, 95% CI [335.670-937.718], P < 0.001) and stage of DN (B = 852.986, 95% CI [297.043-1408.928], P = 0.003) were predictors of cost of pharmacotherapy. Conclusion: Stage of DN and number of drugs prescribed were major determinants of cost of pharmacotherapy.
[FULL TEXT] [PDF]*
|
